Compensations of Executive Directors

Commitments in favor of Executive Directors

Jean-François Dehecq was appointed Honorary Chairman of Sanofi on May 17, 2010.

Equity Compensation

Since 2018, equity compensation for employees, it being precised that its part of the Board of Directors competence under French law, is uniquely made up of performance shares. It serves to align employee and shareholder interests and reinforce employees’ ties to the Company. To limit the potentially dilutive effects for shareholders, only the Chief Executive Officer continues to receive stock options. Under this Board policy, all options or performance shares granted will be subject in their entirety to the achievement of multi-year performance criteria. Thus, plans put in place by the Board since March 5, 2014, are conditioned upon two internal criteria based on Business Net Income and Return on Assets, with a third, external criteria (Total Shareholder Return compared to a panel of pharmaceutical companies) applicable to attributions to the Chief Executive Officer. The Board of Directors commits to report to its shareholders on the level of performance achieved under these conditions in Sanofi's annual reports (Document de référence and U.S. Form 20-F).

For additional information concerning the equity compensation policies of the Board of Directors, please refer to the following documents: